Anti-CD19-chimeric-antigen-receptor-transduced T cells

Anti-CD19-chimeric-antigen-receptor-transduced T cells is a cellular immunotherapy developed by the National Cancer Institute (NCI) for the treatment of B-cell malignancies. This specific therapy involves the genetic modification of T cells—often obtained from a patient's original stem cell donor in the post-allogeneic hematopoietic stem cell transplant (alloHSCT) setting—to express a chimeric antigen receptor (CAR) targeting the CD19 antigen. The CAR construct typically consists of an anti-CD19 single-chain variable fragment (scFv) linked to intracellular signaling domains such as CD28 and CD3-zeta. A distinguishing feature of this NCI protocol is the manufacturing process, which utilizes a culture medium containing interleukin-7 (IL-7), interleukin-21 (IL-21), and the glycogen synthase kinase 3 beta (GSK-3β) inhibitor TWS119. This combination is intended to preserve a memory stem cell phenotype (Tscm) in the final cell product, potentially enhancing the persistence and anti-tumor efficacy of the T cells upon infusion into patients with recurrent or persistent B-cell leukemia or lymphoma.

Other names

Donor-derived anti-CD19 CAR T cellsAllogeneic anti-CD19-CAR-transduced T cellsAnti-CD19-chimeric-antigen-receptor-transduced T cells-National Cancer Institute (NCI)-B-cell leukemia-Hodgkin lymphoma-non-Hodgkin lymphoma